Kappa opioid receptor (κOR) agonists lack the abuse liability and respiratory depression
effects of clinically used mu opioid receptor (μOR) analgesics and are hypothesized to be …

6, 14-ethenomorphinans are semisynthetic opiate derivatives containing an ethylene bridge
between positions 6 and 14 in ring-C of the morphine skeleton that imparts a rigid molecular …

Undue central nervous system (CNS) side effects including dysphoria and sedation remain
to be a challenge for the development of κ opioid receptor (KOR) agonists as effective and …

The search for selective kappa opioid receptor (κOR) agonists with an improved safety
profile is an area of interest in opioid research. In this work, a series of m-substituted analogs …

Research into kappa opioid receptor (KOR) agonists with attenuated central-nervous-system
side effects is a critical focus for developing productive and safe analgesics. Herein, a series …

The discovery and development of novel μ-opioid receptor (MOR) antagonists is a
significant area to combat Opioid Use Disorder (OUD). In this work, a series of para …

κ opioid receptor (κOR) is a subtype of opioid receptors, and there are two major κOR
agonists currently available, morphinans and arylacetamides, which are structurally distinct …

The opioids have been used for more than a thousand years and are not only the most
widely prescribed drugs for moderate to severe pain and acute pain, but also the preferred …

Morphinan-based opioids, derived from natural alkaloids like morphine, codeine and
thebaine, have long been pivotal in managing severe pain. However, their clinical utility is …

Abstract Ring‐C bridged 1‐(pyrimidinyl) tetrahydrothebaines were convenience synthesized
by a consecutive three‐component alkynylation–cyclocondensation sequence starting from …